Envisagenics Closes $2.35M Seed Round and Launches SpliceCore PlatformAn AI drug discovery biotech backed by women biotech VCs NEW YORK, November 30, 2017-- Envisagenics, Inc., a biotechnology company that applies Artificial Intelligence to the genetic sequence of patients to discover new therapies, announced today that is has raised $2.35M in its seed round. The investors include Third Kind Venture Capital (3KVC), Cosine, LLC (NYC biotech investors), Dolby Family Ventures, Dynamk Capital, NY Empire State Development (ESD), and SV Angel.